MetaVia reports 9.1% weight loss in Phase 1 obesity trial for DA-1726, advances pipeline

Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read

Key Changes

• high

  DA-1726 achieved 9.1% weight loss at Day 54 in Phase 1 trial with no serious adverse events or treatment discontinuations, showing continued reduction through Week 8 without plateau—supporting advancement to later-stage obesity studies.

  Item 7.01: Phase 1 Results verify on EDGAR →
• high

  Phase 1 data showed DA-1726 was well-tolerated with mild-to-moderate GI side effects, dose-proportional pharmacokinetics, and statistically significant reductions in waist circumference (9.8 cm) and BMI (3.4 kg/m²) at Day 54.

  Item 7.01: Safety & Efficacy verify on EDGAR →
• medium

  Preclinical data for vanoglipel combined with resmetirom showed 23.6% weight reduction and 83.5% ALT reduction in MASH models, where neither drug alone affected weight—first demonstration of GPR119 plus thyroid hormone receptor beta targeting.

  Item 7.01: Combination Data verify on EDGAR →